Nervous system: Embryonal tumors: Neuroblastoma.

Area of Science:

• Pediatric Oncology
• Cancer Genomics

Background:

• Neuroblastoma is a heterogeneous pediatric cancer originating from neural crest cells, representing the most common extracranial solid tumor in children.
• Prognosis varies widely, from spontaneous regression to aggressive disease, necessitating risk stratification based on patient and tumor characteristics.

Purpose of the Study:

• To review the genomic underpinnings of neuroblastoma pathogenesis.
• To highlight how genetic advancements inform novel therapeutic strategies for improved patient outcomes.

Main Methods:

• Review of genomic features including germline mutations, somatic aberrations, copy number variations, transcriptomics, and epigenetics.
• Analysis of predisposition genes (e.g., ALK, PHOX2B) in familial neuroblastoma.
• Investigation of chromosomal abnormalities and single-nucleotide polymorphisms in sporadic neuroblastoma.

Main Results:

• Genomic features significantly contribute to neuroblastoma development and progression.
• Specific genes like ALK and PHOX2B are implicated in familial forms, while chromosomal aberrations and SNPs play a role in sporadic cases.
• Understanding these genetic drivers is crucial for risk classification and treatment planning.

Conclusions:

• Genomic insights have elucidated the complex pathogenesis of neuroblastoma.
• These discoveries are paving the way for targeted and potentially more effective therapeutic approaches, especially for high-risk neuroblastoma patients.
• Further research into neuroblastoma genomics holds promise for improving long-term survival rates in affected children.